Reporting, Evaluating, Preventing and Treating the Cardiotoxicity Induced by Anticancer Drugs During a Specific Cardio-oncology Consult and Follow up in Routine Care
Condition(s) studied
Investigational drug(s) / intervention(s)
Anti-Cancer Agents: Drugs and treatments used in cancer inducing cardiovascular and metabolic side effects
Study summary
Several Drugs used in routine care in oncology induce rare but often severe or fatal cardiovascular or metabolic side effects. This study will investigate, evaluate, report and treat the cardiovascular side effects of anticancer drugs, through a specific cardiovascular routine checkup and follow-up taking place in several Cardio-oncology programs throughout France. The different including centers will be: Assistance Publique - Hôpitaux de Paris (APHP.6: Pitié-Salpétrière, Saint Antoine and Tenon's hospitals, Paris, France).
Eligibility
Primary outcome measure(s)
- Number of patients having a benefit after this specific cardio-oncology check up and follow up — 5 years
Trial sites (3)
| Facility | City | Region | Status |
|---|---|---|---|
| AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM | Paris | France | Recruiting |
| AP-HP, Saint-Antoine Hospital, Department of cardiology | Paris | France | Recruiting |
| AP-HP, Tenon Hospital, Department of Cardiology | Paris | France | Recruiting |
More Groupe Hospitalier Pitie-Salpetriere trials in France
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT03882580 on ClinicalTrials.gov ↗ ← All trials in France